Interventional Cardiologist, Complex Coronary and CTO Program
Brigham and Women's Hospital, Harvard Medical School
Brian Bergmark, MD is an Interventional Cardiologist in the Complex Coronary and CTO Program at Brigham and Women’s Hospital, Harvard Medical School, and an Investigator at the TIMI Study Group. He received his BA from Stanford University and his MD from Harvard Medical School. Dr. Bergmark completed his residency in Internal Medicine, fellowship in Cardiovascular Medicine, and fellowship in Interventional Cardiology at the Brigham and Women’s Hospital. His research interests include acute coronary syndromes and complex coronary interventions.
Sunday, February 26, 2023
2:00 PM – 4:30 PM ET
Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); AstraZeneca Pharmaceuticals: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing), Grants/Research Support Recipient (Ongoing); Pfizer, Ionis: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Philips, Endovascular Engineering, Abiomed, Terumo, SpectraWAVE: Consulting Fees (e.g., advisory boards) (Ongoing)
Sunday, February 26, 2023
2:00 PM – 2:45 PM ET
Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); AstraZeneca Pharmaceuticals: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing), Grants/Research Support Recipient (Ongoing); Pfizer, Ionis: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Philips, Endovascular Engineering, Abiomed, Terumo, SpectraWAVE: Consulting Fees (e.g., advisory boards) (Ongoing)
Sunday, February 26, 2023
4:13 PM – 4:30 PM ET
Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); AstraZeneca Pharmaceuticals: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing), Grants/Research Support Recipient (Ongoing); Pfizer, Ionis: Contracted Research (Principal Investigators must provide information, even if received by the institution) (Ongoing); Philips, Endovascular Engineering, Abiomed, Terumo, SpectraWAVE: Consulting Fees (e.g., advisory boards) (Ongoing)